Serum Biomarkers in Sudanese Patients with Nonalcoholic Fatty Liver Disease

SHORT COMMUNICATION
Abdelgadir Alamin Altoum, Sofiyat Zayyad, Ibrahim Yousef, Zulekha Shemote

 
For citation: Altoum AA, Zayyad S, Yousef I, Shemote Z. Serum Biomarkers in Sudanese Patients with Nonalcoholic Fatty Liver Disease. International Journal of Biomedicine. 2024;14(3):520-523. doi:10.21103/Article14(3)_ShC
 
Originally published September 6, 2024

Abstract: 

Background: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder. Its pathogenesis is multifactorial, and different pathogenic mechanisms cause differences in its course and outcomes at different clinical stages. This study evaluated serum levels of alpha-fetoprotein (AFP), lipids, and liver enzymes in Sudanese patients with NAFLD.
Methods and Results: This study was conducted at the Advance Diagnostic Center, Bihari Hospital, Khartoum State, Sudan, from September 2021 to November 2022. A total of 80 participants (56 women and 24 men) were divided into two groups: The study group included 40 patients diagnosed with NAFLD, and the control group comprised 40 healthy individuals. All patients underwent an ultrasound examination. The serum levels of AST, ALT, triglycerides (TG), and total cholesterol (TC) were measured using a spectrophotometric method, while AFP levels were assessed using an enzyme-linked immunosorbent assay (ELISA).
Our study revealed a significant increase in the levels of AST, ALT, TG, and AFP in NAFLD patients compared to the control group (P<0.01 in all cases); however, TC levels were not statistically different (P=0.629). Changes in the studied markers did not depend on gender. The correlation analysis showed a moderate positive correlation between TG and AFP (r=0.527, P=0.000) and a weak negative correlation between age and AFP (r=-0.316, P=0.047). The relationship between TC and AFP was statistically insignificant (r=0.246, P=0.126).
Conclusion: Patients with NAFLD exhibit elevated levels of AFP and TG compared to individuals without fatty liver changes. A statistically significant positive correlation between TG and AFP indicates the complexity of the NAFLD pathogenesis.

Keywords: 
nonalcoholic fatty liver disease • alpha-fetoprotein • triglycerides • liver enzymes
References: 
  1. Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S5-10. doi: 10.1097/01.mcg.0000168638.84840.ff. PMID: 16540768.
  2. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012 Jun;55(6):2005-23. doi: 10.1002/hep.25762. PMID: 22488764.
  3. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011 Jan;140(1):124-31. doi: 10.1053/j.gastro.2010.09.038. Epub 2010 Sep 19. PMID: 20858492.
  4. Wong VW. Nonalcoholic fatty liver disease in Asia: a story of growth. J Gastroenterol Hepatol. 2013 Jan;28(1):18-23. doi: 10.1111/jgh.12011. PMID: 23094755.
  5. Dam-Larsen S, Franzmann MB, Christoffersen P, Larsen K, Becker U, Bendtsen F. Histological characteristics and prognosis in patients with fatty liver. Scand J Gastroenterol. 2005 Apr;40(4):460-7. doi: 10.1080/00365520510012217. PMID: 16028442.
  6. Björnsson E, Angulo P. Non-alcoholic fatty liver disease. Scand J Gastroenterol. 2007 Sep;42(9):1023-30. doi: 10.1080/00365520701514529. PMID: 17710666.
  7. Wilkins T, Tadkod A, Hepburn I, Schade RR. Nonalcoholic fatty liver disease: diagnosis and management. Am Fam Physician. 2013 Jul 1;88(1):35-42. PMID: 23939604.
  8. Shin JW, Chung YH. Molecular targeted therapy for hepatocellular carcinoma: current and future. World J Gastroenterol. 2013 Oct 7;19(37):6144-55. doi: 10.3748/wjg.v19.i37.6144. PMID: 24115810; PMCID: PMC3787343.
  9. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011 Sep 22;365(12):1118-27. doi: 10.1056/NEJMra1001683. PMID: 21992124.
  10. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010 May;51(5):1820-32. doi: 10.1002/hep.23594. PMID: 20432259.
  11. Xu P, Xu CF, Wan XY, Yu CH, Shen C, Chen P, Xu GY, Li YM. Association between serum alpha-fetoprotein levels and fatty liver disease: a cross-sectional study. World J Gastroenterol. 2014 Sep 7;20(33):11865-70. doi: 10.3748/wjg.v20.i33.11865. PMID: 25206293; PMCID: PMC4155379.
  12. Chen Y, Zhao Y, Feng L, Zhang J, Zhang J, Feng G. Association between alpha-fetoprotein and metabolic syndrome in a Chinese asymptomatic population: a cross-sectional study. Lipids Health Dis. 2016 Apr 27;15:85. doi: 10.1186/s12944-016-0256-x. PMID: 27121855; PMCID: PMC4848775.
  13. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology. 1998 Jan;27(1):273-8. doi: 10.1002/hep.510270140. PMID: 9425947.
  14. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003 Jul 1;139(1):46-50. doi: 10.7326/0003-4819-139-1-200307010-00012. PMID: 12834318.
  15. Kara M, Genc H, Tapan S, Meral C, Ercin CN, Erdal M, Dogru T. Alpha fetoprotein levels and its relationship with histopathological findings in patients with non-alcoholic fatty liver disease. Eur Rev Med Pharmacol Sci. 2013 Jun;17(11):1536-41. PMID: 23771543.
  16. Babalı A, Cakal E, Purnak T, Bıyıkoğlu I, Cakal B, Yüksel O, Köklü S. Serum α-fetoprotein levels in liver steatosis. Hepatol Int. 2009 Dec;3(4):551-5. doi: 10.1007/s12072-009-9156-8. Epub 2009 Nov 5. PMID: 19890679; PMCID: PMC2790592.
  17. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM. 2010 Feb;103(2):71-83. doi: 10.1093/qjmed/hcp158. Epub 2009 Nov 13. PMID: 19914930; PMCID: PMC2810391.
  18. Petzold G. Role of Ultrasound Methods for the Assessment of NAFLD. J Clin Med. 2022 Aug 5;11(15):4581. doi: 10.3390/jcm11154581. PMID: 35956196; PMCID: PMC9369745.
  19. Chacko KR, Reinus J. Extrahepatic Complications of Nonalcoholic Fatty Liver Disease. Clin Liver Dis. 2016 May;20(2):387-401. doi: 10.1016/j.cld.2015.10.004. Epub 2016 Feb 18. PMID: 27063276.
  20. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol. 2008 Oct;49(4):600-7. doi: 10.1016/j.jhep.2008.06.012. Epub 2008 Jul 2. PMID: 18672311.
  21. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol. 2012 Jun;10(6):646-50. doi: 10.1016/j.cgh.2011.12.039. Epub 2012 Jan 13. PMID: 22245962.
  22. Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014 Mar;59(3):1174-97. doi: 10.1002/hep.26717. Epub 2014 Jan 16. PMID: 24002776.
  23. Roderburg C, Krieg S, Krieg A, Demir M, Luedde T, Kostev K, Loosen SH. Non-alcoholic fatty liver disease (NAFLD) is associated with an increased incidence of chronic kidney disease (CKD). Eur J Med Res. 2023 Apr 17;28(1):153. doi: 10.1186/s40001-023-01114-6. PMID: 37062837; PMCID: PMC10108448.
  24. Liu C, Liu T, Zhang Q, Jia P, Song M, Zhang Q, Ruan G, Ge Y, Lin S, Wang Z, Xie H, Shi J, Han R, Chen Y, Zheng X, Shen L, Deng L, Wu S, Shi H. New-Onset Age of Nonalcoholic Fatty Liver Disease and Cancer Risk. JAMA Netw Open. 2023 Sep 5;6(9):e2335511. doi: 10.1001/jamanetworkopen.2023.35511. PMID: 37747732; PMCID: PMC10520743.

Download Article
Received July 15, 2024.
Accepted August 30, 2024.
©2024 International Medical Research and Development Corporation.